Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer by Yuchen Wu et al.
RESEARCH Open Access
Nuclear-enriched abundant transcript 1 as
a diagnostic and prognostic biomarker in
colorectal cancer
Yuchen Wu1†, Li Yang1†, Jiang Zhao1, Cong Li1, Jia Nie2, Fangqi Liu1, Changhua Zhuo3, Yaxin Zheng4*, Bin Li2*,
Zhimin Wang5* and Ye Xu1*
Abstract
Background: High expression of the long non-coding RNA nuclear-enriched abundant transcript 1 (NEAT1) in
whole blood has been reported in colorectal cancer patients; however, its’ clinical significance and origin are
unclear. We evaluated the diagnostic and prognostic value, and origin of whole blood NEAT1 in colorectal cancer.
Methods: Expression of NEAT1 variants, NEAT1_v1 and NEAT1_v2 were determined using real-time quantitative
PCR. The diagnostic value of whole blood NEAT1 expression was evaluated in test (n = 60) and validation (n = 200)
cohorts of colorectal cancer patients and normal controls (NCs). To identify the origin of NEAT1, its expression was
analyzed in blood, matched primary tumor tissues, para-tumor tissues, metastatic tissues, and also immune cells
from patients or NCs. Function of NEAT1 in colorectal cell lines was also assessed. The correlation of NEAT1 expression
with clinical outcomes was assessed in 191 patients.
Results: Whole blood NEAT1 expression was significantly higher in colorectal cancer patients than in NCs. NEAT1_v1
and NEAT1_v2 expression were highly accurate in distinguishing colorectal cancer patients from NCs (area under the
curve: 0.787 and 0.871, respectively). Knockdown of NEAT1_v1 in vitro could inhibit cell invasion and proliferation, while
knockdown of NEAT1_v2 promoted cell growth. However, whole blood expression was not correlated with matched
tissues. An elevated expression was seen in neutrophils from CRC patients. Furthermore, high expression of NEAT1_v1
was correlated with worse overall survival. In contrast, high expression of NEAT1_v2 alone was correlated with better
overall survival.
Conclusion: Whole blood NEAT1 expression is a novel diagnostic and prognostic biomarker of overall survival in
colorectal cancer. Elevated NEAT1 may derive from neutrophils.
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Background
Current evidence indicates that RNAs play important roles
in oncogenesis and cancer pathogenesis. Considering that
protein-coding sequences constitute only a small proportion
of the genome, non-protein coding RNAs (ncRNAs), which
constitute > 70 % of the human genome [1], are becoming
the subject of increasing attention because of their powerful
regulator roles [2]. It is evident that ncRNA, like micro-
RNAs and long ncRNAs (lncRNA) have roles in the emer-
gence of a wide range of human diseases including cancers
[3–5]. Commonly, lncRNAs are defined as ncRNAs longer
than 200 nucleotides. They have multiple functions includ-
ing acting as structural components, regulating protein
trafficking, regulating transcription and cell metabol-
ism, and modulating protein and RNA activity [6, 7].
Our former study using gene expression microarray re-
vealed the non-protein coding RNAs (ncRNAs) – nuclear-
enriched Abundant Transcript 1 (NEAT1) elevated in
peripheral blood from patients with CRC compared with
healthy participants [8].
NEAT1 is an essential component of nuclear para-
speckles [9, 10]. Paraspeckles are formed by the binding
of Paraspeckle Protein (PSP) 1, PSP2 and p54nrb to the
NEAT1 transcriptional start site [11, 12]. Besides partici-
pating in mediate the development of corpus luteum
and mammary gland [13, 14], nuclear paraspeckles have
various functional significance. Especially, these nuclear
bodies may serve as a “reservoir” for mRNA nuclear re-
tention. They have also been shown to migrate to the
cytoplasm to modulate cytoplasmic proteins and RNA
function [12]. The NEAT1 gene encodes two transcripts:
3.7- kb NEAT1_v1 and 23- kb NEAT1_v2 [15, 16]. Al-
though these two variants share the same transcriptional
start site, NEAT1_v2 has a tRNA-like structure at its 3’
end that is processed by RNaseP cleavage rather than a
poly-A tail [15]. So the two variants shared two distinct
3′-end processing mechanisms: canonical polyadenyla-
tion for NEAT1_v1 and RNase P-mediated cleavage for
NEAT1_v2. NEAT1_v2 has been strongly implicated in
the formation of paraspeckles [12, 15].
In the present study, we determined the diagnostic
and prognostic significance and of whole blood NEAT1
in patients with colorectal cancer.
Results
Whole-blood NEAT1 expressions could distinguish
patients with colorectal cancer from NCs
NEAT1_v1 and NEAT1_v2 levels were significantly
higher in patients with colorectal cancer (n = 30) than in
NCs (n = 30; p = 0.0021 and p < 0.0001, respectively;
Fig. 1a-b). Moreover, ROC analysis revealed that NEAT1
expression could distinguish patients with CRC from
NCs (NEAT1_v1: area under the curve [AUC] = 0.732,
95 % confidence interval [CI] = 0.602–0.838; NEAT1_v2:
AUC = 0.845, 95 % CI = 0.728–0.925; Fig. 1c-d). The
sensitivity and specificity of NEAT1_v1 and NEAT1_v2
in identifying colorectal cancer were 56.7 % and 86.6 %,
83.3 % and 83.3 %, respectively.
The diagnostic value of NEAT1 was validated in a
larger, independent cohort of colorectal cancer pa-
tients (n = 100) and NCs (n = 100). The expression
of both NEAT1 variants was significantly higher in colo-
rectal cancer patients than in NCs (both p < 0.0001;
Fig. 1e–f ). ROC analysis confirmed the diagnostic po-
tential of NEAT1 variants in the validation cohort.
NEAT1_v1 yielded an AUC of 0.787 (95 % CI =
0.724–0.842; Fig. 1g) sensitivity of 69.0 %, and specifi-
city of 79.0 %, and NEAT1_v2 yielded an AUC of
0.871 (95 % CI = 0.816–0.914; Fig. 1h), sensitivity of
70.0 %, and specificity of 96.0 %. Interestingly, whole
blood expression of NEAT1_v1, but not NEAT1_v2,
was higher in patients with stage IV colorectal cancer
compared with other stages (p < 0.0001 and p = 0.132,
respectively; Fig. 1i–j).
Functional assessment of NEAT1 in colorectal cancer cells
We assessed cellular functions such as proliferation, and
invasion after treatments with relevant siRNAs in two
colorectal cancer cell lines. Knockdown of NEAT1_v1
could attenuated the invasive capacity, compared with
cells transfected with NEAT1_v2 and control siRNA.
Moreover, CCK8 assays revealed that down regulation of
NEAT1_v1 lead to significant inhibition of cell growth.
On the contrary, an elevated cell growth was detected
when cells were treated with NEAT1_v2 siRNA (see
Additional file 1).
Validation of NEAT1 expression in tissues
To further validate that whole blood NEAT1 levels
might accurately reflected the concentration in colorec-
tal cancer tissues, we determined the relationship be-
tween NEAT1 expression in primary colorectal cancer
tissues, para-tumor tissues with matched whole blood.
Twenty-nine patients from validation cohort with
stage I to stage IV colorectal cancer were enrolled. How-
ever, no correlation of both NEAT1 variants was found
between tissues and blood (see Additional file 2).
Notably, we found a higher content of NEAT1_v1 in pa-
tients with metastasis colorectal cancer before. So we also
inferred that such higher expression might derived from
metastasis tissues rather than primary tumor tissues.
First of all, we examed another 19 patients who under-
went simultaneously surgery for primary cancer and
hepatic metastasis. Expression of NEAT1_v1 was signifi-
cantly higher in metastatic hepatic tissues compared
with para-tumor and primary colorectal cancer tissues
(p = 0.003). NEAT1_v1 expression was similar between
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Fig. 1 Whole blood NEAT1 expression in screening and validation phase. a, Plots representing different expression of NEAT1_v1 between normal controls
(NC, n=30) and colorectal cancer (CRC, n=30) patients. b, Plots representing different expression of NEAT1_v2. c, Whole blood NEAT1_v1 yielded an AUC
value of 0.732 (95 % CI: 0.602-0.838), with 56.7 % sensitivity and 86.7 % specificity in distinguishing colorectal cancer patients from NCs. d, Whole blood
NEAT1_v2 yielded an AUC value of 0.845 (95% CI: 0.728-0.925), with 83.3 % sensitivity and 83.3 % specificity in distinguishing colorectal cancer patients
from NCs. e, Plots representing different expression of NEAT1_v1 between another groups of NC (n=100) and CRC patients (n=100). f, Plots representing
different expression of NEAT1_v2. G, ROC curve of NEAT1_v1 from another groups yielded an AUC value of 0.787 (95 % CI: 0.724-0.842), with 69.0 %
sensitivity and 79.0 % specificity in distinguishing colorectal cancer patients from NCs. h, ROC curve of NEAT1_v2 from another groups yielded an AUC
value of 0.871 (95 % CI: 0.816-0.914), with 70.0 % sensitivity and 96.0 % specificity in distinguishing colorectal cancer patients from NCs. i, Plots illustrating
different levels of NEAT1_v1 versus TNM staging. j, Plots illustrating different levels of NEAT1_v2 versus TNM staging. *P<0.05, **P<0.001, ***P<0.0001
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primary tumor and para-tumor tissues (p = 0.8214).
NEAT1_v2 expression was not significantly different
among para-tumor, primary tumor, and metastatic hep-
atic tissues (p = 0.076; Fig. 2a–b). These results were
somewhat in accordance with what we found in whole
blood. However, after comparing the expression of both
NEAT1 variants in whole blood and metastasis tis-
sues, we also found no correlation between them (see
Additional file 3), which meant that there might be
other reasons for such difference in whole blood ra-
ther than tissue origins.
Neutrophil expression of NEAT1 variants was higher in
colorectal cancer patients than in NCs
There was no correlation of NEAT1 expression be-
tween whole blood and tissues. Considering that im-
mune cells comprise the majority of peripheral blood
cells, we also determined NEAT1 expression from dif-
ferent subgroups of immune cells between colorectal
cancer patients and NCs.
We separated neutrophils, monocytes, CD4-positive
cells (mainly CD4-positive T helper cells), CD8-positive
cells (mainly cytotoxic T cells), and CD4/CD8 double-
negative cells (mainly B cells and natural killer cells)
from peripheral blood (see Additional file 4).
Neutrophils had the highest expression of both NEAT1
variants among the immune cell types. Expression of both
variants in neutrophils were higher in colorectal cancer
patients than in NCs (NEAT1_v1, p = 0.001; NEAT1_v2,
p = 0.015; Fig. 3a–b). Moreover, when comparing neutro-
phils’ expression in different cancer stages, an elevated
content of NEAT1_v1 but not NEAT1_v2 was found in
stage IV patients, which was in accordance with what we
found in whole blood (NEAT1_v1 Stage IV, p < 0.001,
Fig. 3c–d). Overall, we testified that NEAT1 expression in
peripheral neutrophils might be the key point in distin-
guishing CRC patients from healthy people.
Whole blood expression of NEAT1 was significantly
correlated with overall survival in patients with
colorectal cancer
After proving the diagnostic value of whole blood ex-
pression of NEAT1, we proceeded to verify its function
in prognosis. We determined the correlation of whole
blood NEAT1_v1 and NEAT1_v2 expression with clinical
outcomes in 191 colorectal cancer patients with available
clinicopathological data. NEAT1_v1 were significantly
higher in colorectal cancer patients with distant metasta-
ses (M1) than in those without metastasis (M0; p = 0.023),
whereas NEAT1_v2 levels did not differ between the M1
and M0 groups (p = 0.9917; Table 1 and Fig. 4a).
The median follow-up duration was 56 (2–83) months.
Patients with high NEAT1_v1 expression had shorter
OS and median survival times than patients with low
NEAT1_v1 expression (p = 0.003; Fig. 4b).
Univariate analysis revealed that nodal status (N0/N1
p < 0.001; N0/N2 p = 0.001), distant metastasis (p < 0.001),
lymphatic/vascular invasion (p < 0.001), perineural inva-
sion (p = 0.001), extranodal tumor deposit (p = 0.005),
American Joint Committee on Cancer stage (p < 0.001),
and NEAT1_v1 expression (p = 0.004) were significantly
associated with OS. However, in the multivariate analysis,
only nodal status (N0/N1 p < 0.001; N0/N2 p = 0.017) and
distant metastasis (p < 0.001) remained significantly inde-
pendent prognostic factors for OS (Table 2). NEAT1_v1
expression was found to have limited prognostic value for
OS (p = 0.068).
Fig. 2 NEAT1 expression differed in the para-tumor, tumor and matched liver metastasis. (a) Significantly higher expression of NEAT1_v1 was
detected in liver metastasis samples versus para-tumor tissues and tumor tissues (p = 0.003). (b) No significant difference was detected among
primary tumor tissues , para-tumor tissues and liver metastasis (p = 0.076). *A two-tailed p value ≤0.05 was considered statistically significant
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Although OS did not differ in patients with different
levels of NEAT1_v2 (p = 0.281, Fig. 4c), higher expression
of NEAT1_v2 without higher expression of NEAT1_v1
(high expression of NEAT1_v2 alone) represented bet-
ter OS compared with low and high expression of
both variants (p = 0.036 and p < 0.001, respectively)
(Fig. 4d). There was no significant difference in OS
between patients with low expression of both variants
compared with those with high expression of both
variants (p = 0.303). Multivariate analysis, revealed that
high expression of NEAT1_v2 alone could be an independ-
ent prognostic factor for improved OS (p = 0.0038). More-
over, we found that higher expression of NEAT1_v1 was
almost combined with higher expression of NEAT1_v2
(107/111 patients).
Discussion
Colorectal cancer is one of the most common malignan-
cies worldwide. It is the third common cancer and the
fifth leading cause of death in China [17, 18]. Early
diagnosis of colorectal cancer is important for improving
treatment response, patients’ survival, and quality of life.
Blood-based tests to detect tumor markers, such as
carcinoembryonic antigen, may help to evaluate disease
status, but their accuracy and efficacy are controversial
[19, 20]. Ideally, diagnostic tests for the early detection
of colorectal cancer should be simple, accurate, and
minimally invasive. Considerable studies have identified
and developed novel biomarkers for diagnosis, progno-
sis, and predicting treatment response [21–24]. Using in-
dependent patient cohorts, we demonstrated for the first
time that whole blood NEAT1_v1 and NEAT1_v2 may
be valuable diagnostic biomarkers in colorectal cancer.
However, NEAT1_v2 seemed to be a more sensitive and
specific biomarker compared with NEAT1_v1 (70 % vs.
69.0 % and 96.0 % vs. 79.0 %, respectively).
Our study also demonstrated the prognostic potential of
NEAT1 expression in colorectal cancer. Whole blood
NEAT1_v1 expression was higher in patients with distant
metastasis, and patients with high NEAT1_v1 expression
Fig. 3 Different expression of NEAT1 isoforms in 5 groups of immune cells sorted from peripheral blood. (a) The NEAT1_v1 expression was different in
five groups of immune cells, and varied dramatically in neutrophils from two groups of people (p = 0.018). (b) The NEAT1_v2 expression in CRC
patients was also higher than that in normal controls (p = 0.0057). All graphs showed mean values ± SEM. *p < 0.05. (c) NEAT1_v1 was higher in
neutrophils fro stage IV colorectal cancer patients. (d) No significant difference was detected in NEAT1_v2 expression in different stage
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had poorer OS. However, NEAT1_v1 expression was
found not to be an independent prognostic factor for OS
in the multivariate analysis. Furthermore, NEAT1_v1 was
higher in hepatic metastatic tissues than in primary colo-
rectal cancer tissues, suggesting that elevated NEAT1_v1
expression in whole blood may originate from metastatic
tissues. Further studies are needed to assess the potential
contribution of other metastatic sites such as the lung and
bone to NEAT1_v1 expression in the peripheral whole
blood of colorectal cancer patients.
Interestingly, despite sharing the same transcriptional
start site, NEAT1_v1 and NEAT1_v2 appeared to have
different roles in predicting clinical outcomes. We found
that high NEAT1_v2 combined with low NEAT1_v1 ex-
pression was associated with improved OS in colorectal
cancer patients. Furthermore, NEAT1_v2 expression was
an independent prognostic factor for OS in the multi-
variate analysis. In contrast, elevated NEAT1_v1 was
associated with poor OS because of its association with
metastasis. We also found that patients with simul-
taneous low or high expression of NEAT1_v1 and
NEAT1_v2 had poor OS. Based on these findings, we
believe that NEAT1_v2 may play a protective role in
colorectal cancer. In patients with low expression of
both variants, NEAT1_v2 is unable to perform its
protective function. On the other hand, in patients with
high expression of both variants, the putative protective
role of NEAT1_v2 may be masked by high NEAT1_v1 ex-
pression, resulting in poor OS and tendency toward me-
tastasis. Although mechanisms underlying this dynamic
equilibrium may be difficult to investigate, it is clear that
the differential expression of NEAT1 variants in whole
blood has prognostic value in colorectal cancer.
The ratio of the two variants of NEAT1 is regulated by
differential use of polyadenylation signals. Naganuma et
al. demonstrated that one of the paraspeckle proteins
Table 1 Relationship between NEAT1 and clinical features of patients with colon cancer in the whole blood
Clinical variables Classification N NEAT1_v1 NEAT1_v2
Mean P value Mean P value
Gender Male 101 6.26 0.098 1.65 0.987
Female 90 5.38 1.65
Age (years)a <56 100 5.60 0.253 1.62 0.769
≥56 91 6.21 1.69
Tumor (T) stage T1–2 26 6.16 0.287 1.46 0.476
T3–4 165 5.80 1.68
Nodal (N) status N0 95 5.45 0.287 1.54 0.464
N1 48 6.02 1.65
N2 48 6.45 1.87
Distant metastasis (M) M0 170 5.52 0.023* 1.63 0.532
M1 21 8.49 1.84
AJCC stageb I–II 94 5.45 0.144 1.55 0.374
III–IV 97 6.23 1.74
Lymphovascular invasion No 141 5.55 0.497 1.70 0.463
Yes 50 6.67 1.52
Perineural invasion No 163 5.55 0.549 1.67 0.701
Yes 28 7.54 1.55
Extranodal tumor deposits No 163 5.53 0.139 1.66 0.800
Yes 28 7.66 1.58
Differentiation G1–G2 149 5.92 0.587 1.64 0.880
G3–G4 42 5.57 1.68
Pathology Adenocarcinoma 164 5.93 0.412 1.68 0.465
Mucinous or signet-ring carcinoma 27 5.30 1.46
Maximum size (cm)a <5 118 6.02 0.344 1.67 0.687
>5 73 5.48 1.58
*A two-tailed p value ≤0.05 was considered statistically significant
aThe mean age and tumor size, respectively
bAbbreviations: AJCC, American Joint Committee on Cancer (AJCC)
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(PSPs), HNRNPK competed with CPSF6 (CFIm68) for
binding to NUDT21 (CFIm25), leading to the accumula-
tion of NEAT1_v2 [25]. Interestingly, Chioniso et al.
indenified CFIm25 as a tumour suppresser as RNA 3′-
end-processing factor in glioblastoma [26]. So further re-
search on the polyadenylation signals in NEAT1 edition
and its function in colorectal cancer is required. Further-
more, other roles of NEAT1 in mediating tumorigenesis
and metastasis has recently received increasing attention
[27–29]. Choudhry et al. found that NEAT1 was regu-
lated by hypoxia-inducible factor-2 and hypoxia-induced
NEAT1 accelerates cellular proliferation, improves cell
survival, and reduces apoptosis (28). Chakravarty et al.
reported that androgen receptor antagonist-resistant
prostate cancer cells express high levels of NEAT1,
which was shown to drive their oncogenic growth (29).
In the present study, we demonstrated that NEAT1_v1
could improve tumor cells growth and invasion, while
NEAT1_v2 had reverse function in proliferation, which
was somewhat in corresponding with the prognostic po-
tential of whole blood NEAT1 expression. Moreover, we
found that NEAT1_v1 was highly expressed in metastatic
hepatic tissues from colorectal cancer patients. These
findings suggest that NEAT1 has both pro-oncogenic and
pro-metastatic effects in colorectal cancer. A recently
study demonstrated that NEAT1 and another lncRNA,
metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) colocalize to hundreds of genomic sites and
may have complementary functions [30]. MALAT1, an 8.1
kb lncRNA , is overexpressed in many malignant tumors,
including human primary colorectal cancer. MALAT1 up-
regulation has been reported to promote colorectal cancer
development via its target protein A-kinase anchor pro-
tein [31]. Together, these studies indicate that NEAT1 has
a potentially complex role in driving tumorigenesis.
In the present study, we also investigated the possible
sources contributing to the differential whole blood ex-
pression of NEAT1 between colorectal cancer patients
Fig. 4 Whole blood NEAT1 expression patients with metastasis and its correlation with overall survival. (a) NEAT1_v1 but not NEAT1_v2 was
higher in patients’ blood who had metastasis (p = 0.023). (b) Patients with higher expression of NEAT1_v1 tended to have worse overall survival
(p = 0.003). (c) Compared to NEAT1_v1, no significant difference was found in NEAT1_v2 to overall survival. (d) Higher expression of NEAT1_v2
alone (higher expression of NEAT1_v2 without higher expression of NEAT1_v1) had better overall survival than that of both low expressions
(p = 0.036) and both high expressions (p < 0.001). OS between patients from both low expressions and both high expressions had no significant
difference (p = 0.303).*A two-tailed p value ≤0.05 was considered statistically significant
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and NCs. The expression of NEAT1 was higher in pa-
tients’ blood than tissues. We detected higher expression
in metastasis liver tissues and proved its mechanism in
tumor cells proliferation and invasion. The in vitro experi-
ments enclosed a contradictory mechanism of NEAT1
variants in tumor development and invasion, which
was in accord with the prognostic potential in whole
blood. NEAT1_v1 acted as a carcinogenic factor, while
NEAT1_v2 was a protective one. However, fact that
no correlation was found between whole blood and tissues
could not be ignored. One of the possible explanation
might be the degradation of NEAT1 in whole blood which
derived from tissues. Moreover, expression of NEAT1 was
higher in whole blood than in tissues. This suggests that
cancer-related sources do not fully account for the in-
creased expression in whole blood. Our findings indicate
that neutrophils may mostly contribute to the elevated ex-
pression of NEAT1 in whole blood, as both NEAT1_v1
and NEAT1_v2 expression were higher in neutrophils
from colorectal cancer patients than in those from NCs,
and a higher NEAT1_v1 expression was also detected in
neutrophils from stage IV patients, which was in corres-
pondence with the difference found in whole blood.
The functional roles of peripheral blood and tumor-
associated neutrophils have been investigated in cancer
patients. Clinical research has primarily evaluated the
prognostic role of peripheral neutrophils in cancer pa-
tients [32–34]. These studies have shown that a high
Table 2 Cox analysis of the prognostic variables on the overall survival in patients ( Whole blood)
Prognosis variables Overall survival
P value HR (95 % CI)
Univariate analysis
NEAT1_v1, Low/High 0.004* 0.415 (0.227–0.758)
NEAT1_v2, Low/High 0.285 1.421 (0.746–2.708)
NEAT1_v2, High Alonea 0.006* 0.426 (0.231–0.784)
Gender, Male/Female 0.399 1.290 (0.714–2.330)
Age, <56/≥56 yearsb 0.967 0.988 (0.544–1.793)
Tumor (T) stage, T1–2/T3–4 0.124 0.399 (0.124–1.288)
Nodal (N) status, N0/N1 <0.001* 0.120 (0.056–0.257)
N0/N2 <0.001* 0.297 (0.143–0.617)
Distant metastasis (M), M0/M1 <0.001* 0.102 (0.055–0.188)
Lymphatic/vascular invasion, No/Yes <0.001* 0.243 (0.135–0.438)
Perineural invasion, No/Yes 0.001* 0.342 (0.179–0.653)
Extranodal tumor deposit, No/Yes 0.005* 0.389 (0.201–0.753)
AJCC Stagec, I–II/III–IV <0.001* 0.205 (0.066–0.426)
Differentiation, G1–G2/G3–G4 0.058 0.543 (0.289–1.022)
Pathology, Adenocarcinoma/Mucinous or signet-ring carcinoma 0.712 0.859 (0.384–1.923)
Size, <5/≥5b 0.598 1.187 (0.627–2.247)
Multivariate analysis
NEAT1_v1, Low/High 0.068
NEAT1_v2, High Alonea 0.038* 0.519 (0.280–0.965)
Nodal (N) status, N0/N1 <0.001* 0.199 (0.088–0.452)
N0/N2 0.017* 0.402 (0.189–0.851)
Distant metastasis (M), M0/M1 <0.001* 0.193 (0.099–0.374)
Lymphatic/vascular invasion, No/Yes 0.996
Perineural invasion, No/Yes 0.366
Extranodal tumor deposit, No/Yes 0.645
AJCC Stagec, I–II/III–IV 0.498
*A two-tailed p value ≤0.05 was considered statistically significant
aHigh expression of NEAT1_v2 with low expression of NEAT1_v1
bThe mean age and tumor size, respectively
cAbbreviations: AJCC, American Joint Committee on Cancer (AJCC)
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neutrophil to lymphocyte ratio is an independent
prognostic factor for survival. On the other hand,
fundamental research has mostly focused on tumor-
associated neutrophils [35] and their migration [36–38],
proliferation, correlation with other immune cells such as
myeloid-derived suppressor cells [39–41], and paradoxical
functions on tumorgenesis [42–45]. Therefore, the func-
tional roles of peripheral neutrophils in tumorigenesis are
still unclear. Although the role of NEAT1 in immune sys-
tem function, especially during viral infection (e.g., human
immunodeficiency viral infection), has been intensely in-
vestigated [46–48], its function of NEAT1 in neutrophils
has not been fully addressed. Considering that NEAT1
acts as one of the main structural components in para-
speckles and possess a wide range of known or unknown
function, its role in peripheral neutrophils of colorectal
cancer patients is warranted. Whether increased NEAT1
expression in neutrophils is a cause or by-product of
tumorigenesis and whether there are other potential
sources of NEAT1 are still unclear.
Our findings indicated the significant promise of whole
blood NEAT1 expression as a diagnostic marker in colo-
rectal cancer and thus, warrants confirmation in larger
studies. These studies should include patients in the same
general condition and use a uniform method to detect
RNA expression to help eliminate any potential coinciden-
tal bias. Differential expression of NEAT1 variants may be
potentially relevant in other cancer types; therefore, further
studies in patients with other cancer types are also needed.
Moreover, despite no correlation of NEAT1 expression be-
tween whole blood and tissues was found, an elevated ex-
pression in metastasis was certainty. So basic research on
NEAT1 in carcinogenesis is indispensable and is in process.
Moreover, higher NEAT1 expression in CRC patients’
whole blood did not correlated with tissues and it might
originated from its different content in neutrophils. In
summary, we believe that such difference in whole blood
derived from numerous sources, but mainly from neutro-
phils. However, the function of NEAT1 on neutrophils
needs to be uncovered in the future.
In conclusion, our study established and validated
NEAT1 as a new diagnostic biomarker in colorectal can-
cer. In addition, NEAT1_v1 and NEAT1_v2 expression
were associated with different prognostic outcomes. Ele-
vated whole blood NEAT1 expression may derive, in
part, from metastatic tissues and neutrophils. Further re-
search is needed to fully clarify the clinical significance
of high neutrophil NEAT1 expression in colorectal can-
cer patients.
Materials and Methods
Study design and patients
The study design and patient characteristics are confirmed
(see Additional files 5 and 6). Study participants were
recruited from the Fudan University Shanghai Cancer
Center (China) between 2006 and 2012. Patients who
underwent any preoperative radiotherapy or chemother-
apy before blood collection, and those with inflammatory
bowel disease, hereditary colorectal cancer, or other rare
tumor types were excluded. Healthy volunteers with nor-
mal colonoscopy results for colorectal cancer served as
the normal controls (NCs). The study was approved by
the Medical Ethics Committee of Fudan University
Shanghai Cancer Center, and written informed con-
sent was obtained from all participants. TNM classifica-
tion and differentiation grade were determined according
to the 2010 American Joint Committee on Cancer criteria
(7th edition). Clinicopathological data were obtained
retrospectively from the patients’ electronic medical
records.
The diagnostic value of whole blood NEAT1 was ini-
tially evaluated in a test cohort comprised of 30 colorec-
tal cancer patients and 30 NCs and then validated in a
large, independent cohort of 100 patients and 100 NCs.
Tumor tissues, para-tumor tissues of 29 patients (stage I
to stage IV) from validation cohort were collected and
compared with matched blood sample. Moreover, an-
other 19 patients receiving simultaneously resection of
primary tumor tissues and liver metastasis were also en-
rolled to investigate the correlation of NEAT1 between
whole blood and tissues.
Subsequently, a survival analysis was performed in an
additional 191 patients with available clinicopathological
and prognostic data. Finally, to identify the origin of
whole blood NEAT1 expression, NEAT1 expression in
primary colorectal cancer and matched hepatic meta-
static tissues and immune cells was determined. Primary
colorectal cancer and matched hepatic metastatic tissues
were obtained from 19 colorectal cancer patients who
had undergone simultaneous resection of colorectal can-
cer and hepatic metastasis. Immune cells were isolated
from peripheral blood samples obtained from 12 colo-
rectal cancer patients and 12 NCs.
Blood and tissue collection and immune cell isolation
All blood samples were obtained prior to surgery or adju-
vant therapy. To investigate NEAT1 expression for clinical
outcomes, peripheral blood (2.5 mL) samples were col-
lected into PAXgene Blood RNA Tubes (PreAnalytiX).
Normal and cancerous colorectal tissues and matched
hepatic metastatic tissues were collected immediately after
surgery, washed in cold PBS, and stored in RNAlater RNA
Stabilization Reagent (Qiagen) at −20 °C for future use.
For immune cell sorting, peripheral blood samples (20
mL) were collected and stored in EDTA anticoagulant
tubes. All immune cells were isolated < 12 h after collec-
tion. Neutrophils were isolated using improved Ficoll
Solution (TBD). CD4-positive and CD8-positive T cells
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were isolated from peripheral blood mononuclear cells by
fluorescence-activated cell sorting (Aria II Cell Sorter; BD
Biosciences) with fluorescein isothiocyanate-conjugated
anti-CD4 and allophyocyanin-conjugated anti-CD8 mono-
clonal antibodies (BD Biosciences) according to manufac-
turer’s instructions. All fluorescence-activated cell sorting
data were analyzed using FlowJo software (Tree Star).
RNA isolation and quantitative real-time reverse
transcription-PCR
Total RNA was extracted from peripheral blood samples
using the PAXgene Blood RNA System (PreAnalytiX).
Total RNA was isolated from immune cells and tissues
using TRIzol Reagent (Sigma) according to the manu-
facturer’s instructions. RNA was quantified using a
NanoDrop spectrophotometer. For each sample, RNA
(320 ng) was reverse transcribed using the QuantiTect
Reverse Transcription Kit (Qiagen). cDNA was amplified
using SYBR Premix DimerEraser (Perfect Real Time;
Takara Biotechnology), and real-time quantification was
performed using the Applied Biosystems 7900HT Fast
Real-Time PCR System (Life Technologies). As we had
previously identified DECR1 (2,4-dienoyl-coenzyme A re-
ductase 1 mitochondrial) as a stably expressed reference
gene in whole blood samples [8, 49, 50], it was used as a
reference gene for the blood sample analysis. β-actin was
used as a reference gene for the tissue sample analysis. Pri-
mer sequences are provided in Additional file 7. All real-
time PCR products were verified by DNA sequencing.
Relative gene expression levels were estimated using
the comparative Ct method of relative quantification,
normalizing the Ct values relative to the reference
gene. Relative gene expression is presented as 2-ΔCt,
where ΔCt = Ct colorectal cancer –Ct Control.
Cell lines and cell culture conditions
Two human colorectal cancer cell lines (HCT116, LOVO)
were obtained from the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China) and were
cultured in McCoy’s 5a and F-12 K Medium respectively.
All medium contained 10 % fetal bovine serum (FBS).
Medium and FBS were obtained from GIBCO® (Life
Technologies, USA).
Invasion and proliferation assays
NEAT1 is located in cell nucleus and is hard to knock-
down with simple siRNA stably. So we used a mixed
siRNA pool to silence NEAT1 variants respectively. In
transwell assay, transfected cells (3 × 105cells/well) were
seeded in serum-free medium in 12-well Transwell
Chamber (BD Biosciences, USA). 50ul diluted Matrigel
was plated in chambers. They were placed in cell culture
plates containing 10 % FBS and incubated for 48 h. After
that, membranes were washed, fixed and stained with
Crystal Violet. Invading cells in 10 microscopic fields
were counted.
Cell Counting Kit 8 (CCK-8, Donjindo) was used to
assessed cell viability. Treated cells were seeded into 96-
well plates at an initial density of 1 × 103cells/well. After
24, 48, 72, and 96 h of cultivation, CCK-8 solution was
added to each well and incubated for 2 h. The absorb-
ance was measured by scanning with a microplate reader
(MRX; Dynex Technologies, West Sussex, United King-
dom) at 450 nm.
Each independent experiment was performed 3 times.
Results are presented as mean ± SE.
Statistical analyses
Statistical analyses were performed using SPSS v.19.0
(IBM Corp.). Receiver operating characteristic (ROC)
analysis was performed to determine the ability of whole
blood NEAT1 expression to distinguish colorectal cancer
patients from NCs. The Kolmogorov-Smirnov test was
used to verify the normal distribution of cardinal vari-
ables. Exploratory comparison of normally distributed
and non-normally distributed independent groups was
performed using t-tests and Mann–Whitney U (2 groups)
or Kruskal-Wallis tests (>2 groups), respectively. The
Friedman test was used to analyze differences among 3
paired samples. Pearson analysis was performed to explore
the correlation of NEAT1 between blood and tissues.
Overall survival (OS) was estimated using Kaplan–Meier
curves and compared using the log-rank test. OS was cal-
culated as the time from date of definitive diagnosis to
date of death by any cause. Prognostic factors were de-
termined using Cox regression analysis. A two-tailed
p value < 0.05 was considered statistically significant.
Ethics, consent and permissions
Written informed consent was obtained from all par-
ticipants. Study was approved by the Medical Ethics
Committee of Fudan University Shanghai Cancer Center
(reference number 050432-4-1212B).
Consent to publish
We have obtained consent from all participants to report
data to publish.
Additional files
Additional file 1: Figure S1. Functional assays of NEAT1 on colorectal
cancer cells. Knockdown of NEAT1_v1 expression suppressed cell invasion
and proliferation, while knockdown of NEAT1_v2 promote cell proliferation.
(PDF 395 kb)
Additional file 2: Table S1. Correlation of NEAT1 expression between
blood and matched tissues. Blood and matched tissues were collected
from 46 patients (Stage I-IV). Correlation analysis was performed and p-value
was present in the table. (PDF 303 kb)
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Additional file 3: Table S2. Correlation of NEAT1 expression between
blood and matched tissues in patients with simultaneously surgery for
primary cancer and hepatic metastasis. Blood and matched tissues were
collected from 19 patients with simultaneously surgery. Correlation analysis
was performed and p-value was present in the table. (PDF 151 kb)
Additional file 4: Figure S2. 5 groups of immune cells separated from
peripheral blood from patients and healthy donors. Neutrophils were
isolated using improved Ficoll Solution. Monocytes, CD4+Lymphocytes,
CD8+ Lymphocytes, and CD4−CD8− Lymphocytes were isolated from
peripheral blood mononuclear cells by fluorescence-activated cell sorting
with anti-CD4 and anti-CD8 monoclonal antibodies. (PDF 85.8 kb)
Additional file 5: Figure S3. Study design. The blood gene expression
was identified using a screening set and an independent validation set.
Blood from another 191 patients was detected for clinical outcomes.
Primary lesion and metastasis with matched blood were also investigated.
Another group of blood were detected on immune cells. (PDF 87.5 kb)
Additional file 6: Table S3. Characteristics of the CRC and control
populations. (PDF 183 kb)
Additional file 7: Table S4. Primer sequences for NEAT1 and reference
genes. (PDF 132 kb)
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